Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Interpace Biosciences, Inc. (IDXGD) had Normalized Income after Taxes of $0.27M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$9.13M |
|
$0.16M |
|
$3.48M |
|
$5.65M |
|
$8.81M |
|
$0.32M |
|
$0.01M |
|
$0.33M |
|
$0.33M |
|
$0.27M |
|
$0.27M |
|
$0.16M |
|
|
Normalized Income after Taxes |
$0.27M |
$0.32M |
|
$0.56M |
|
27.70M |
|
27.71M |
|
$0.01 |
|
$0.01 |
|
| Balance Sheet Financials | |
$10.97M |
|
$1.62M |
|
$23.58M |
|
$34.55M |
|
$4.95M |
|
-- |
|
$6.35M |
|
$11.30M |
|
$23.24M |
|
$23.24M |
|
$23.24M |
|
27.70M |
|
| Cash Flow Statement Financials | |
$0.38M |
|
$-0.20M |
|
-- |
|
$2.50M |
|
$2.69M |
|
$0.18M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.22 |
|
-- |
|
-- |
|
-- |
|
-- |
|
61.91% |
|
3.52% |
|
3.52% |
|
-- |
|
3.61% |
|
1.73% |
|
$0.18M |
|
-- |
|
-- |
|
-- |
|
0.26 |
|
-- |
|
1.45 |
|
62.20 |
|
1.14% |
|
1.14% |
|
0.77% |
|
1.14% |
|
$0.84 |
|
$0.01 |
|
$0.01 |
|